General Information of Drug (ID: DMCWT4L)

Drug Name
PUP-1 Drug Info
Synonyms MMP-12 inhibitor (chronic obstryctive pulmonary disorder) Abiogen
Indication
Disease Entry ICD 11 Status REF
Chronic obstructive pulmonary disease CA22 Investigative [1]
Cross-matching ID
TTD Drug ID
DMCWT4L

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Neovastat DMXTYWJ Non-small-cell lung cancer 2C25.Y Phase 1 [2]
FP-025 DMH1NXO Asthma CA23 Phase 1 [3]
PMID29130358-Compound-Figure17(12) DMML4PA N. A. N. A. Patented [4]
PMID29130358-Compound-Figure17(10) DMVA15O N. A. N. A. Patented [4]
PMID29130358-Compound-Figure17(11) DMSZA9L N. A. N. A. Patented [4]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [5]
AZD1236 DML3RSF Chronic obstructive pulmonary disease CA22 Discontinued in Phase 2 [6]
V85546 DMLFMSY Inflammation 1A00-CA43.1 Discontinued in Phase 1 [7]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [8]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Matrix metalloproteinase-12 (MMP-12) TTXZ0KQ MMP12_HUMAN Inhibitor [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636).
2 Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
3 Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies. Expert Rev Proteomics. 2015;12(5):445-7.
4 Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
5 Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
6 Clinical pipeline report, company report or official report of AstraZeneca (2009).
7 Clinical pipeline report, company report or official report of Vernalis.
8 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9 Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.